Trending...
- Creole101 Launches Multilingual Dictionary App with 50,000+ Entries, Vocabulary Games and Haitian Cultural Resources
- Pittsburgh Digital Marketing Agency Moves to Babcock Boulevard in the North Hills
- DayPass launches in ChatGPT and Claude
SAN DIEGO, June 17, 2024 ~ In a recent announcement, Primrose Bio, Inc. revealed that it has received a significant equity investment from 1315 Capital, a healthcare-focused growth equity firm based in Philadelphia. This investment will provide the necessary funds for the company to further develop and expand its three major offerings.
Primrose Bio, Inc., also known as "Primrose," is dedicated to developing and licensing manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines. With this new investment, the company is well-positioned to advance its solutions for therapeutic protein and nucleic acid manufacturing with both current and future partners.
One of Primrose's key offerings is Prima RNApols™, which are proprietary RNA polymerase enzymes that have been shown to significantly improve mRNA manufacturing. These enzymes have been found to increase yields by up to 5 times, eliminate double-stranded RNA, and enhance cap incorporation compared to the commonly used T7 RNA polymerase standard.
Another major offering from Primrose is Pfenex Expression Technology®, a validated microbial expression system that has been used in five approved drugs. This technology consistently demonstrates 10-20 times higher yields compared to other systems such as E.coli, CHO, and yeast-based systems. It also boasts an unparalleled success rate in producing complex proteins.
More on The PennZone
Lastly, Primrose offers PeliCRM®, the only commercially available CRM197 conjugate vaccine carrier protein used in approved products. This technology plays a crucial role in the production of vaccines.
Dr. Helge Zieler, CEO of Primrose Bio, Inc., expressed excitement about the partnership with 1315 Capital. "We are thrilled to have the support of such a high-quality organization and team at 1315 Capital who share our vision of expanding opportunities in biomanufacturing technologies for the pharmaceutical industry," he said.
Matt Reber, Partner at 1315 Capital, also shared his enthusiasm for this collaboration. "There has been a tremendous amount of innovation in therapeutics over the last decades, and relatively little in their production systems," he stated. "Primrose's validated technology platforms address an increasingly important challenge facing the industry as drugs get more complex, and pricing pressure continues to mount."
With this new investment, Primrose Bio, Inc. is poised to make significant strides in the biomanufacturing industry and continue to provide cutting-edge solutions for therapeutic protein and nucleic acid manufacturing.
Primrose Bio, Inc., also known as "Primrose," is dedicated to developing and licensing manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines. With this new investment, the company is well-positioned to advance its solutions for therapeutic protein and nucleic acid manufacturing with both current and future partners.
One of Primrose's key offerings is Prima RNApols™, which are proprietary RNA polymerase enzymes that have been shown to significantly improve mRNA manufacturing. These enzymes have been found to increase yields by up to 5 times, eliminate double-stranded RNA, and enhance cap incorporation compared to the commonly used T7 RNA polymerase standard.
Another major offering from Primrose is Pfenex Expression Technology®, a validated microbial expression system that has been used in five approved drugs. This technology consistently demonstrates 10-20 times higher yields compared to other systems such as E.coli, CHO, and yeast-based systems. It also boasts an unparalleled success rate in producing complex proteins.
More on The PennZone
- Roots for Boots to Participate in 2026 Adams County Community Foundation Giving Spree
- Simpalm Staffing Launches Tax Preparer Staffing for U.S. CPA Firms
- ASSIST Software Wins Volkswagen Challenge for Automated Quality Inspection
- National Literacy and Workforce Readiness Crisis Sparks New Program Launching in Birmingham
- New England Consulting Partners Celebrates 25 Years of Turnaround Management Solutions
Lastly, Primrose offers PeliCRM®, the only commercially available CRM197 conjugate vaccine carrier protein used in approved products. This technology plays a crucial role in the production of vaccines.
Dr. Helge Zieler, CEO of Primrose Bio, Inc., expressed excitement about the partnership with 1315 Capital. "We are thrilled to have the support of such a high-quality organization and team at 1315 Capital who share our vision of expanding opportunities in biomanufacturing technologies for the pharmaceutical industry," he said.
Matt Reber, Partner at 1315 Capital, also shared his enthusiasm for this collaboration. "There has been a tremendous amount of innovation in therapeutics over the last decades, and relatively little in their production systems," he stated. "Primrose's validated technology platforms address an increasingly important challenge facing the industry as drugs get more complex, and pricing pressure continues to mount."
With this new investment, Primrose Bio, Inc. is poised to make significant strides in the biomanufacturing industry and continue to provide cutting-edge solutions for therapeutic protein and nucleic acid manufacturing.
0 Comments
Latest on The PennZone
- Stand Strong Fencing of Hatfield Turns Every October Project Into a Cancer Donation
- New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of
- Former Goddard Enterprises Managing Director Anthony Ali Joins STS Capital Partners as Managing Director and Partner
- Heritage at Manalapan Announces Limited-Time Mortgage Rate Buydown on Select Quick Move-In Homes
- Good Organics Now at Pop Up Grocer NYC With October 30 Sampling Event
- KeysCaribbean Announces Temporarily Reduced Rates At Village at Hawks Cay Villas
- Commercial Manufacturing Validation Completed as November 10 FDA Milestone Approaches; Critical FDA Milestone Close: NRx Pharmaceuticals NAS DAQ: NRXP
- Electives Launches "Electives for Everyone," Making Live Expert-Led Learning Available to Every Employee
- Tax Tops the List as Wealthy Brits Plan Their Exit, La Vida Survey Finds
- "The Tree of Cinema" Installation Brought Film History and Its Audiences Together at TIFF 2026
- Detroit Lawyer Steals $600,000 Settlement Meant to Protect Child
- The Great Junk Hunt Makes Its Highly Anticipated Stop in Philadelphia (Oaks)!
- Heritage at South Brunswick Announces Special Townhome Mortgage Rate Buydown
- Heritage at Hopewell Announces Limited-Time Mortgage Rate Buydown on Select Quick Move-In Townhomes
- Air Force Veteran Sean Douglas Delivers Powerful Suicide Prevention Presentations to Hundreds of Marines at Camp Pendleton
- Ashley Russo Receives Linny Lifetime Achievement Award
- How to Choose a Heating Repair Company in Philadelphia
- Renew Integrative Health Publishes Updated Peptide Therapy Guide to Help Patients Understand Their Options
- Lehigh County Drug and Alcohol Celebrates Grand Opening of Journeys
- Timbrana Addresses the Missing Follow-Through in Commercial Construction Projects